Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.
HBIO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for HBIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Harvard Bioscience Inc ranked in the 43th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Harvard Bioscience Inc ended up being:
The company's balance sheet shows it gets 67% of its capital from equity, and 33% of its capital from debt. Notably, its equity weight is greater than only 23.81% of US equities in the Healthcare sector yielding a positive free cash flow.
Harvard Bioscience Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.54. This coverage rate is greater than that of merely 22.02% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Harvard Bioscience Inc? See ICLR, DGX, GILD, CRL, and CAH.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth. In addition, we expect to complete the streamlining of our UK operation next quarter.